Prestige Consumer Healthcare Inc. (PBH) is a publicly traded Healthcare sector company. As of May 21, 2026, PBH trades at $46.40 with a market cap of $2.21B and a P/E ratio of 12.04. PBH moved +1.96% today. Year to date, PBH is -24.46%; over the trailing twelve months it is -46.11%. Its 52-week range spans $42.62 to $90.04. Analyst consensus is strong buy with an average price target of $82.89. Rallies surfaces PBH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Prestige Forecasts 2027 Organic Growth, Posts $246M Cash Flow to Fund Acquisitions: Prestige expects organic growth to return in fiscal 2027 driven by improved eye care shipments and new launches like Fleet Mini Enema. It generated $246 million in free cash flow in fiscal 2026 to back acquisitions of Pillar 5, Breathe Right and Lacorium despite a 4% revenue decline.
| Metric | Value |
|---|---|
| Price | $46.40 |
| Market Cap | $2.21B |
| P/E Ratio | 12.04 |
| EPS | $3.93 |
| Dividend Yield | 0.31% |
| 52-Week High | $90.04 |
| 52-Week Low | $42.62 |
| Volume | 120 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.09B |
| Net Income | $190.30M |
| Gross Margin | 54.70% |
4 analysts cover PBH: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $82.89.